The gut microbiota and inflammatory bowel disease

Seminars in Immunopathology

Volumn 37, Issue 1, 2015, Pages 47-55

  Matsuoka, Katsuyoshi ^a   Kanai, Takanori ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Crohn s disease; Dysbiosis; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

MESALAZINE; PLACEBO; PROBIOTIC AGENT; STEROID; VSL3;

BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DYSBIOSIS; ENTERITIS; FECAL MICROBIOTA TRANSPLANTATION; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; METAGENOMICS; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DISTRIBUTION; THERAPY EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; MICROFLORA;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICROBIOTA;

EID: 84925486076     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-014-0454-4     Document Type: Review

References (76)

1. Rutgeerts P et al (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 338:771–774
2. Khan KJ et al (2011) Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106:661–673. doi:10.1038/ajg.2011.72
3. Ananthakrishnan AN et al (2011) Strategies for the prevention of postoperative recurrence in Crohn’s disease: results of a decision analysis. Am J Gastroenterol 106:2009–2017. doi:10.1038/ajg.2011.237
4. Jostins L et al (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119–124. doi:10.1038/nature11582
5. Eckburg PB et al (2005) Diversity of the human intestinal microbial flora. Science 308:1635–1638. doi:10.1126/science.1110591
6. Frank DN et al (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785. doi:10.1073/pnas.0706625104
7. Manichanh C et al (2006) Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55:205–211. doi:10.1136/gut.2005.073817
8. Willing BP et al (2010) A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139(1844–1854):e1841. doi:10.1053/j.gastro.2010.08.049
9. Tong M et al (2013) A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One 8:e80702. doi:10.1371/journal.pone.0080702
10. Gophna U et al (2006) Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol 44:4136–4141. doi:10.1128/jcm.01004-06
11. Scanlan PD et al (2006) Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn’s disease. J Clin Microbiol 44:3980–3988. doi:10.1128/jcm.00312-06
12. Peterson DA et al (2008) Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3:417–427. doi:10.1016/j.chom.2008.05.001
13. Sokol H et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731–16736. doi:10.1073/pnas.0804812105
14. Wang W et al (2014) Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol 52:398–406. doi:10.1128/jcm.01500-13
15. Andoh A et al (2011) Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 46:479–486. doi:10.1007/s00535-010-0368-4
16. Takaishi H et al (2008) Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 298:463–472. doi:10.1016/j.ijmm.2007.07.016
17. Martinez C et al (2008) Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 103:643–648. doi:10.1111/j.1572-0241.2007.01592.x
18. Ott SJ et al (2008) Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol 46:3510–3513. doi:10.1128/jcm.01512-08
19. Andrews CN et al (2011) Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 34:374–383. doi:10.1111/j.1365-2036.2011.04732.x
20. Gevers D et al (2014) The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15:382–392. doi:10.1016/j.chom.2014.02.005
21. Lepage P et al (2005) Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 11:473–480
22. Swidsinski A et al (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54
23. Schultsz C et al (1999) The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117:1089–1097
24. Walker AW et al (2011) High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 11:7. doi:10.1186/1471-2180-11-7
25. Lepage P et al (2011) Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141:227–236. doi:10.1053/j.gastro.2011.04.011
26. Varela E et al (2013) Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 38:151–161. doi:10.1111/apt.12365
27. Joossens M et al (2011) Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60:631–637. doi:10.1136/gut.2010.223263
28. Frank DN et al (2011) Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17:179–184. doi:10.1002/ibd.21339
29. Dey N et al (2013) Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol 13:131. doi:10.1186/1471-230x-13-131
30. Feller M et al (2007) Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis 7:607–613. doi:10.1016/s1473-3099(07)70211-6
31. Selby W et al (2007) Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 132:2313–2319. doi:10.1053/j.gastro.2007.03.031
32. Barnich N, Darfeuille-Michaud A (2007) Adherent-invasive Escherichia coli and Crohn’s disease. Curr Opin Gastroenterol 23:16–20. doi:10.1097/MOG.0b013e3280105a38
33. Ohkusa T et al (1993) Bacterial invasion into the colonic mucosa in ulcerative colitis. J Gastroenterol Hepatol 8:116–118
34. Ohkusa T et al (2002) Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 17:849–853
35. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N (2003) Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52(1):79–83
36. Ohkusa T et al (2005) Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40:1334–1342. doi:10.1080/00365520510023648
37. Lees CW et al (2011) New IBD genetics: common pathways with other diseases. Gut 60:1739–1753. doi:10.1136/gut.2009.199679
38. Wehkamp J et al (2004) NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut 53:1658–1664. doi:10.1136/gut.2003.032805
39. Noguchi E et al (2009) A Crohn’s disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 10:471–479. doi:10.1038/ni.1722
40. Cooney R et al (2010) NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16:90–97. doi:10.1038/nm.2069
41. Salzman NH et al (2010) Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 11:76–83. doi:10.1038/ni.1825
42. VanDussen KL et al (2014) Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn’s disease. Gastroenterology 146:200–209. doi:10.1053/j.gastro.2013.09.048
43. Cadwell K et al (2010) Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell 141:1135–1145. doi:10.1016/j.cell.2010.05.009
44. Adolph TE et al (2013) Paneth cells as a site of origin for intestinal inflammation. Nature 503:272–276. doi:10.1038/nature12599
45. Kim SC et al (2005) Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128:891–906
46. Garrett WS et al (2007) Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131:33–45. doi:10.1016/j.cell.2007.08.017
47. Qin J et al (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65. doi:10.1038/nature08821
48. Gill SR et al (2006) Metagenomic analysis of the human distal gut microbiome. Science 312:1355–1359. doi:10.1126/science.1124234
49. Morgan XC et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79. doi:10.1186/gb-2012-13-9-r79
50. Furusawa Y et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450. doi:10.1038/nature12721
51. Pitcher MC et al (2000) The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46:64–72
52. Ivanov II et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485–498. doi:10.1016/j.cell.2009.09.033
53. Caselli M et al (2013) Segmented filamentous bacteria-like organisms in histological slides of ileo-cecal valves in patients with ulcerative colitis. Am J Gastroenterol 108:860–861. doi:10.1038/ajg.2013.61
54. van Nood E et al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415. doi:10.1056/NEJMoa1205037
55. Bennet JD, Brinkman M (1989) Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1:164
56. Anderson JL et al (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36:503–516. doi:10.1111/j.1365-2036.2012.05220.x
57. Angelberger S et al (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108:1620–1630. doi:10.1038/ajg.2013.257
58. Kump PK et al (2013) Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19:2155–2165. doi:10.1097/MIB.0b013e31829ea325
59. Kunde S et al (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56:597–601. doi:10.1097/MPG.0b013e318292fa0d
60. Gionchetti P et al (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309
61. Mimura T et al (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53:108–114
62. Tursi A et al (2010) Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105:2218–2227. doi:10.1038/ajg.2010.218
63. Sood A et al (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7:1202–1209. doi:10.1016/j.cgh.2009.07.016, 1209 e1201
64. Miele E et al (2009) Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104:437–443. doi:10.1038/ajg.2008.118
65. Soo I et al (2008) VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol 22:237–242
66. Rembacken BJ et al (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635–639
67. Kruis W et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623. doi:10.1136/gut.2003.037747
68. Kruis W et al (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853–858
69. Kamada N et al (2008) Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect Immun 76:214–220. doi:10.1128/iai.01193-07
70. Zocco MA et al (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23:1567–1574. doi:10.1111/j.1365-2036.2006.02927.x
71. Bousvaros A et al (2005) A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839
72. Schultz M et al (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 4:5. doi:10.1186/1471-230x-4-5
73. Furrie E et al (2005) Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54:242–249. doi:10.1136/gut.2004.044834
74. Kato K et al (2004) Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20:1133–1141. doi:10.1111/j.1365-2036.2004.02268.x
75. Ishikawa H et al (2003) Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22:56–63
76. Hayashi A et al (2013) A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13:711–722. doi:10.1016/j.chom.2013.05.013